We are live on ! Find out more
PHS

PFM Health Sciences Portfolio holdings

AUM $1.1B
1-Year Est. Return 57.92%
This Fund
S&P 500
This Quarter Est. Return
-5.61%
1 Year Est. Return
+57.92%
3 Year Est. Return
+183.93%
5 Year Est. Return
+283%
10 Year Est. Return
+2,507.28%
AUM
$2.67B
AUM Growth
-$263M
Cap. Flow
-$103M
Cap. Flow %
-3.85%
Top 10 Hldgs %
36.14%
Holding
81
New
10
Increased
17
Reduced
15
Closed
13

Top Buys

Rank Stock Value
1
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$74.9M
2
JNJ icon
Johnson & Johnson
JNJ
+$44.2M
3
BDX icon
Becton Dickinson
BDX
+$41.6M
4
SRRA
Sierra Oncology, Inc. Common Stock
SRRA
+$30.5M
5
MOH icon
Molina Healthcare
MOH
+$22.7M

Top Sells

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$124M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$46.3M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$41.5M
4
NBIX icon
Neurocrine Biosciences
NBIX
+$33.6M
5
HCA icon
HCA Healthcare
HCA
+$29M

Sector Composition

Rank Sector Weight
1 Healthcare 92.79%
2 Financials 0.34%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ERAS icon
26
Erasca
ERAS
$6.19B
$41.2M 1.54%
4,791,406
-399,999
-8% -$4.63M
CRBU icon
27
Caribou Biosciences
CRBU
$149M
$40.1M 1.5%
4,370,545
+278,236
+7% +$2.93M
EW icon
28
Edwards Lifesciences
EW
$51.6B
$39.8M 1.49%
338,155
-35,337
-9% -$3.96M
ICLR icon
29
Icon
ICLR
$12.2B
$38.5M 1.44%
158,183
– –
PEN icon
30
Penumbra
PEN
$12.7B
$37M 1.38%
166,719
-10,369
-6% -$2.3M
TMO icon
31
Thermo Fisher Scientific
TMO
$212B
$36.7M 1.37%
62,143
– –
WAT icon
32
Waters Corp
WAT
$36.8B
$36.5M 1.37%
117,634
– –
CAH icon
33
Cardinal Health
CAH
$55.2B
$36.3M 1.36%
639,783
– –
SNDX icon
34
Syndax Pharmaceuticals
SNDX
$1.7B
$35.5M 1.33%
2,043,377
-60,135
-3% -$1.01M
SRRA
35
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$34.1M 1.27%
+1,062,888
New +$30.5M
MCK icon
36
McKesson
MCK
$96.8B
$32.4M 1.21%
105,811
-71,189
-40% -$19.4M
AZN icon
37
AstraZeneca
AZN
$241B
$30M 1.12%
226,150
-166,724
-42% -$20M
CTLT
38
DELISTED
CATALENT, INC.
CTLT
$28.4M 1.06%
256,096
-70,604
-22% -$7.37M
JNCE
39
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$27M 1.01%
3,972,868
– –
KRTX
40
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$26.3M 0.98%
207,116
+30,025
+17% +$3.38M
CI icon
41
Cigna
CI
$74.5B
$22.6M 0.84%
+94,135
New +$22M
ELV icon
42
Elevance Health
ELV
$83B
$21M 0.79%
42,734
– –
NTLA icon
43
Intellia Therapeutics
NTLA
$1.58B
$20.9M 0.78%
287,909
+109,687
+62% +$9.29M
HRTX icon
44
Heron Therapeutics
HRTX
$96.8M
$20.1M 0.75%
3,512,348
– –
HCA icon
45
HCA Healthcare
HCA
$88B
$20.1M 0.75%
80,128
-115,493
-59% -$29M
DXCM icon
46
DexCom
DXCM
$32.9B
$18.9M 0.71%
148,084
+130,208
+728% +$14.2M
ISEE
47
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$16.9M 0.63%
1,005,216
– –
SOPH icon
48
SOPHiA GENETICS
SOPH
$477M
$15.6M 0.58%
2,014,024
+61,872
+3% +$695K
GILD icon
49
Gilead Sciences
GILD
$163B
$14.9M 0.56%
249,884
+172,891
+225% +$11.1M
OSH
50
DELISTED
Oak Street Health, Inc.
OSH
$14.1M 0.53%
523,644
+244,287
+87% +$5.15M
1
2
3 4

Similar funds

DAM
Delta Asset Management Memphis, Tennessee $1.1B AUM 14.89% 1-Year Est. Return
MAM
Mark Asset Management New York $1.1B AUM 43.79% 1-Year Est. Return
LCM
Legato Capital Management San Francisco, California $1.1B AUM 61.65% 1-Year Est. Return
DAM
DLD Asset Management New York $1.1B AUM 4.68% 1-Year Est. Return
KCM
Khrom Capital Management Miami Beach, Florida $1.09B AUM 14.82% 1-Year Est. Return
CF
Corebridge Financial Houston, Texas $1.09B AUM 1.85% 1-Year Est. Return
MIA
MMBG Investment Advisors Miami, Florida $1.09B AUM 30.96% 1-Year Est. Return
YL
YCG LLC Austin, Texas $1.1B AUM 4.87% 1-Year Est. Return

PFM Health Sciences's Q1 2022 Portfolio in Review

As of Q1 2022, PFM Health Sciences held 81 positions worth $2.67B, down 8.9% from $2.94B the previous quarter. Its ten largest holdings account for 36% of the portfolio.

PFM Health Sciences withdrew a net $103M in Q1 2022, closing 13 positions and reducing 15 holdings. Its most notable exit was AbbVie, an estimated $124M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 94% a quarter earlier, followed by Financials.

Against the trend, PFM Health Sciences opened a new position in Jazz Pharmaceuticals worth $80.4M.

  • PFM Health Sciences's largest Q1 2022 buy was Jazz Pharmaceuticals: 516,406 shares worth $80.4M.
  • PFM Health Sciences added most to Johnson & Johnson in Q1 2022, an estimated $44.2M increase.
  • PFM Health Sciences's biggest Q1 2022 reduction was HCA Healthcare, cutting an estimated $29M.
  • PFM Health Sciences fully exited AbbVie in Q1 2022, selling an estimated $124M.
  • PFM Health Sciences's ten largest holdings make up 36% of its $2.67B portfolio in Q1 2022.
  • PFM Health Sciences opened 10 new positions and closed 13 in Q1 2022.
  • PFM Health Sciences's portfolio value fell 8.9% quarter-over-quarter to $2.67B.

Based on PFM Health Sciences's 13F filing for Q1 2022, filed 16 May 2022.